Fluid Restriction for Patients with Heart Failure: Current Evidence and Future Perspectives

Author:

Kato Naoko P.1ORCID,Nagatomo Yuji2ORCID,Kawai Fujimi3ORCID,Kitai Takeshi4,Mizuno Atsushi5ORCID

Affiliation:

1. Department of Health, Medicine and Caring Sciences, Division of Nursing Sciences and Reproductive Health, Linköping University, 581 83 Linköping, Sweden

2. Department of Cardiology, National Defense Medical College, Tokorozawa 359-8513, Japan

3. Library, Department of Academic Resources, St. Luke’s International University, Tokyo 104-0044, Japan

4. Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Centre, Suita 564-8565, Japan

5. Department of Cardiovascular Medicine, St. Luke’s International Hospital, Tokyo 104-8560, Japan

Abstract

Fluid restriction has long been believed to benefit patients with heart failure by counteracting the activated renin–angiotensin aldosterone system and sympathetic nervous activity. However, its effectiveness remains controversial. In this paper, we summarized the current recommendations and reviewed the scientific evidence on fluid restriction in the setting of both acute decompensated heart failure and compensated heart failure. While a recent meta-analysis demonstrated the beneficial effects of fluid restriction on both all-cause mortality and hospitalization compared to usual care, several weaknesses were identified in the assessment of the methodological quality of the meta-analysis using AMSTAR 2. Further randomized controlled trials with larger sample sizes are needed to elucidate the benefits of fluid restriction for both clinical outcomes and patient-reported outcomes in patients with heart failure.

Funder

Kamprad Family Foundation

Swedish Heart Lung Foundation

Publisher

MDPI AG

Reference77 articles.

1. Heart failure epidemiology and novel treatments in Japan: Facts and numbers;Konishi;ESC Heart Fail.,2016

2. Global Burden of Cardiovascular Diseases and Risks, 1990–2022;Mensah;J. Am. Coll. Cardiol.,2023

3. Heart failure drug treatment: The fantastic four;Bauersachs;Eur. Heart J.,2021

4. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC;McDonagh;Eur. J. Heart Fail.,2022

5. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Heidenreich;Circulation,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3